<DOC>
	<DOCNO>NCT01686997</DOCNO>
	<brief_summary>Morbid obesity increase medical problem western country . It 's related comorbidities diabetes mellitus , hypertension , OSAS , arthrosis hypercholesterolemia . The Roux-en-Y Gastric Bypass ( RYGB ) effective surgical therapy morbidly obese patient . A part patient disappointing result , weight regain long term . Some study show weight reduction increase biliopancreatic limb patient morbid obesity . The objective study investigate effect variation length biliopancreatic limb weight reduction morbidly obese patient undergo RYGB-surgery . We hypothesize longer biliopancreatic limb result weight reduction . The study design prospective , randomize control trial . The patient randomize 2 group : standard RYGB ( short biliopancreatic limb ) long biliopancreatic limb RYGB .</brief_summary>
	<brief_title>Effect Long Biliopancreatic Limb RYGB Weight Loss Comorbidities</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<criteria>Patient eligible bariatric surgery accord Fried guideline Primary Gastric bypass BMI 35 40 comorbidity BMI &gt; 40 Redo operation medical history : gastric sleeve/ mason / gastric band BMI level Exclusion criterion bariatric surgery ( Fried Guidelines ) Patients language problem interveins follow medical advises Genetic disease intervens follow medical advises Chronic bowel disease Nephrologic ( MDRD &lt; 30 ) liver disease ( AST/ALT twice norm ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bariatric surgery</keyword>
	<keyword>Roux-en-Y Gastric Bypass</keyword>
</DOC>